David Warren Carter Net Worth

The estimated Net Worth of David Warren Carter is at least $2.04 Million dollars as of 2 November 2009. David Carter owns over 40,000 units of Immunogen stock worth over $1,405,800 and over the last 21 years David sold IMGN stock worth over $629,950.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

David Carter IMGN stock SEC Form 4 insiders trading

David has made over 5 trades of the Immunogen stock since 2007, according to the Form 4 filled with the SEC. Most recently David sold 45,000 units of IMGN stock worth $359,550 on 1 November 2010.

The largest trade David's ever made was exercising 50,000 units of Immunogen stock on 17 June 2008 worth over $69,000. On average, David trades about 8,095 units every 62 days since 2003. As of 2 November 2009 David still owns at least 45,000 units of Immunogen stock.

You can see the complete history of David Carter stock trades at the bottom of the page.

What's David Carter's mailing address?

David's mailing address filed with the SEC is , , , , .

Insiders trading at Immunogen

Over the last 21 years, insiders at Immunogen have traded over $72,947,831 worth of Immunogen stock and bought 303,125 units worth $974,603 . The most active insiders traders include Biochem Incshire Pharmaceut..., Capital, L.P.Morton Holding..., and Mark J Enyedy. On average, Immunogen executives and independent directors trade stock every 34 days with the average trade being worth of $2,554,057. The most recent stock trade was executed by Stacy Ann Coen on 2 February 2024, trading 14,350 units of IMGN stock currently worth $448,294.

What does Immunogen do?

immunogen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics with its proprietary antibody-drug conjugate (adc) technology. the company's lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor α-positive ovarian cancers and other solid tumors. leading healthcare companies have licensed rights to use immunogen's technology to develop novel anticancer therapies, and roche's marketed product, kadcyla, utilizes immunogen's adc technology. more information about the company can be found at www.immunogen.com.

Complete history of David Carter stock trades at Immunogen

Immunogen executives and stock owners

Immunogen executives and other stock owners filed with the SEC include:

• Mark Enyedy,
  President, Chief Executive Officer, Director
• Anna Berkenblit,
  Senior Vice President and Chief Medical Officer
• Thomas Ryll,
  Vice President, Technical Operations
• Mark Joseph Enyedy,
  Pres, CEO & Director
• Dr. Anna Berkenblit,
  Sr. VP & Chief Medical Officer
• Dr. Theresa G. Wingrove,
  Sr. VP of Regulatory Affairs & Quality
• Stacy A. Coen,
  Sr. VP & Chief Bus. Officer
• Stephen McCluski,
  Independent Chairman of the Board
• Kristine Peterson,
  Independent Director
• Richard Wallace,
  Independent Director
• Dean Mitchell,
  Independent Director
• Mark Goldberg,
  Independent Director
• Stuart Arbuckle,
  Independent Director
• Theresa Wingrove,
  Senior Vice President - Regulatory Affairs and Quality
• Stacy Coen,
  Senior Vice President and Chief Business Officer
• Susan Altschuller,
  Chief Financial Officer, Senior Vice President
• Kristen Harrington-Smith,
  Sr. VP & Chief Commercial Officer
• Audrey Bergan,
  VP & Chief HR Officer
• Courtney O'Konek,
  Sr. Director of Corp. Communications & Investor Relations
• Dr. Thomas Ryll,
  Sr. VP of Technical Operations
• Renee Lentini,
  VP of Fin., Principal Accounting Officer & Corp. Controller
• Peter J. Williams,
  VP, Business Development
• John Lambert,
  Senior Vice President
• Joseph J Villafranca,
  Director
• Richard J. Gregory,
  Executive VP & CSO
• Charles Q Morris,
  Executive VP & CDO
• Daniel M Junius,
  Chief Financial Officer
• David Brannon Johnston,
  Chief Financial Officer
• Ellie Harrison,
  VP & Chief HR Officer
• Howard H Pien,
  Director
• Lauren White,
  SVP, CFO AND PFO
• David G Foster,
  V.P.-Fin., Prin. Acctg. Off.
• Blaine H. Mc Kee,
  EVP & Chief Business Officer
• Nicole Onetto,
  Director
• Craig Barrows,
  Executive VP, General Counsel
• Sandra Poole,
  Senior VP, Tech Operations
• Mark B Skaletsky,
  Director
• Gregory D Perry,
  Chief Financial Officer
• James J O'leary,
  Vice President
• Biochem Incshire Pharmaceut...,
  
• Karleen Marie Oberton,
  Senior Corporate Controller
• Virginia Lavery,
  VP and Senior Controller
• Gregg Beloff,
  Vice President and CFO
• Christopher U Missling,
  Chief Financial Officer
• Capital, L.P.Morton Holding...,
  
• David Warren Carter,
  Director
• Mitchel Sayare,
  Chief Executive Officer
• John Tagliamonte,
  VP, Business Development
• Stuart Feiner,
  Director
• Pauline Jen Ryan,
  VP Business Development
• Walter Blattler,
  Executive Vice President
• Isabel Kalofonos,
  SVP & CHIEF COMMERCIAL OFFICER
• Tracey L Mc Cain,
  Director
• Michael Vasconcelles,
  EVP R&D & MEDICAL AFFAIRS
• Daniel Char,
  SVP & CHIEF LEGAL OFFICER
• Helen M. Thackray,
  Director
• Kristen Harrington Smith,
  SVP & CHIEF COMMERCIAL OFFICER
• Renee Lentini,
  VP & PRIN ACCTG OFFICER